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Abstract.  In this paper, a Working Group on Gastro- 
Oesophageal Reflux discusses recommendations for the 
first line diagnostic and therapeutic approach of gastro- 
oesophageal reflux disease in infants and children. All 
members of the Working Group agreed that infants 
with uncomplicated gastro-oesophageal reflux can be 
safely treated before performing (expensive and often 
unnecessary) complementary investigations. However, 
the latter are mandatory if symptoms persist despite 
appropriate treatment. Oesophageal pH monitoring of 
long duration (18-24 h) is recommended as the investi- 
gation technique of choice in infants and children with 
atypical presentations of gastro-oesophageal r flux. Up- 
per gastro-intestinal endoscopy in a specialised centre is 
the technique of choice in infants and children present- 
ing with symptoms uggestive of peptic oesophagitis. 
* Working roup on gastro-oesophageal reflux disease of the Euro- 
pean Society of Paediatric Gastroenterology andNutrition 
Correspondence to: Y. Vandenplas 
I Abbreviation: GOR = gastro-oesophageal reflux 
Prokinetics, still a relatively new drug family, have al- 
ready obtained adefinitive place in the treatment ofgas- 
tro-oesophageal reflux disease in infants and children, 
especially if "non-drug" treatment (positional therapy, 
dietary recommendations, etc.) was unsuccessful. It was 
the aim of the Working Group to help the paediatrician 
with this consensus statement and guide-lines to estab- 
lish a standardised management of gastro-oesophageal 
reflux disease in infants and children. 
Introduct ion 
Gastro-oesophageal ref ux (GOR) disease is a frequent 
cause of morbidity in childhood. This paper summarises 
the opinion of members of a Working Group of the 
European Society of Paediatric Gastro-enterology and 
Nutrition (ESPGAN) on GOR disease. Due to the re- 
cent development of new drugs and the wide availability 
of oesophageal pH monitoring, it is the opinion of the 
members that a proposal regarding the diagnostic and 
therapeutic approach would help the general paediatri- 
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cian with patient management. These guidelines have 
the inconvenience that they are necessarily generalisa- 
tions, they are not perfect, and should if necessary, be 
tailored for the individual patient. 
Four principal aims were continuously considered: 
(1) the recommendations should be suitable for as large 
a patient population as possible (with the inconvenience 
that for some individual patients these recommendations 
will not be appropriate); (2) the recommendations should 
be helpful to first-line physicians (family doctors and 
paediatricians) in the management of infants and chil- 
dren with (suspected) gastro-oesophageal reflux; (3) 
the widespread application of these recommendations 
requires that the investigations and management should 
be as non invasive as possible; (4) attention has been 
given to the expenses related to a widespread application 
of these recommendations and their repercussion i the 
financial planning of health resources. 
Def'mition 
GOR is best defined as the involuntary passage of gastric 
contents into the oesophagus. The origin of the gastric 
contents can vary: saliva, ingested foods and drinks, 
gastric secretions, pancreatic or biliary secretions that 
have first refluxed into the stomach (duodeno-gastric e-
flux). 
Various unsatisfactory terms have been used in the 
past, illustrating that the concentration was limited to 
certain aspects of the problem. In Great Britain, hiatal 
hernia or partial thoracic stomach was often used, em- 
phasizing an anatomical spect [8]. Chalasia was a popu- 
lar term in North America, indicating that GOR is often 
related to a lax lower oesophageal sphincter, thus a func- 
tional defect hat occurs so frequently that it is often con- 
sidered as physiological in infants [5]. GOR does not 
specify any specific aetiology and is the preferred term. 
The definition of pathological GOR has been discussed 
in the previous Consensus Statement of this Working 
Group [43]. 
Vomiting is used as a synonym for emesis, and means 
that the refluxed material comes out of the mouth "with 
a certain degree of strength" or "more or less vigorous- 
ly", usually involuntary and with sensation of nausea. 
Regurgitation is used if the reflux dribbles effortlessly 
out of the mouth, and is mostly restricted to infancy 
(birth-12 months). Rumination means the patients 
chews and swallows the refluxed gastric contents, and 
implies that at least part of the refluxes occurs effortless 
and voluntarily. 
Clinical presentation 
Symptoms of reflux may be observed in normal individu- 
als, but in those cases they ar only observed incidentally, 
and they occur more often and are more severe in patho- 
logical situations. Reflux disease is a matter of quantity 
of reflux: healthy and sick people do not differ in the 
presence or absence of reflux, but in its frequency and 
intensity, and in the presence of associated symptoms 
Table 1. Symptoms ofGOR disease 
A. Oesophageal manifestations 
Specific symptoms 
Regurgitation 
Nausea 
Vomiting 
Symptoms possibly related to vomiting or complications ofGOR ~ 
Symptoms related to anaemia (iron deficiency anaemia) 
Haematemesis and melaena 
Dysphagia ( s a symptom of oesophagitis or due to stricture 
formation) 
Weight loss and/or failure to thrive 
Epigastric or retrosternal pain 
"Non-cardiac ngina-like" chest pain 
Pyrosis or heartburn, pharyngeal burning 
Belching, postprandial fuiness 
Irritable oesophagus 
General irritability (infants) 
B. Unusual presentations 
GOR related to chronic respiratory disease (bronchitis, 
asthma, laryngitis, pharyngitis, etc.) b 
Asthma (caused by GOR)  b 
GOR caused by asthma (CARA) b 
Cystic fibrosis [13] 
Sandifer Sutcliffe syndrome 
Rumination 
Apnoea, apparent life threatening event and sudden infant 
death syndrome [24] 
C. Associated to congenital nd~or central nervous ystem 
abnormalities 
(intracranial turnouts, cerebral palsy, psychomotor retardation) 
a A number of these symptoms may also be caused by other mech- 
anisms 
b According to some authors, these associations are still specula- 
tive 
[3], Most of the clinical problems related to GOR are 
caused by excessive passage of (acid) gastric contents 
into the oesophagus. The usual manifestations and un- 
usual presentations of GOR disease are listed in Table 1. 
Infants with a Roviralta Astoul syndrome have pyloric 
stenosis associated with hiatal hernia. 
Vomiting is the most common symptom of "primary" 
GOR disease but is of course also a manifestation of
many other diseases. Such "secondary" GOR may for 
example occur in infections (urinary tract infection, gas- 
tro-enteritis, etc.), metabolic disorders and food allergy. 
"Secondary" GOR is not discussed in this paper. It is ob- 
vious that in "primary" GOR-disease antireflux treat- 
ment is mandatory, and that in "secondary" GOR-dis- 
ease the primary disease should be treated, and not the 
GOR itself. Anatomical or functional abnormalities lead 
to an increased incidence and duration of GOR and thus 
increased emesis (primary GOR). "Secondary" GOR or 
vomiting is the result of a stimulation of the vomiting 
centre in the dorsolateral reticular formation by all kinds 
of efferent impulses (visual stimuli, the olfactory epi- 
thelium, labyrinths, pharynx, gastro-intestinal and uri- 
nary tracts, testes . . . .  ). 
In recent years there has been a tendency to relate a 
wide range of diseases or symptoms to GOR. Examples 
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are as varied as chronic otitis, dental enamel etching, 
halitosis (bad smelling breath), globus sensation, and 
laryngeal lesions, which all are reported in patients with 
GOR. A major shortcoming of most of these reports is 
that there was no attempt to establish aclear causal and 
temporal relationship between both phenomena. 
Therapeutic approach 
Therapeutic approaches range from cheap and easy to 
expensive and complex. Considering both the experi- 
ence of the members of the Working Group and the lit- 
erature, a schematic approach is presented (Table 2). 
All recommendations do not necessarily have to be pre- 
scribed for each patient. The Table 2 is cumulative: i.e. 
phase 2 therapy consists of phase 1 treatment and the 
specific recommendations listed under phase 2. 
Phase 1 treatment 
Phase 1. A. positional treatment. The influence of posi- 
tion on the incidence and duration of GOR episodes has 
been demonstrated in adults, children and infants both 
in asymptomatic healthy controls and symptomatic indi- 
viduals. Orenstein et al. [33] demonstrated that infants 
had up to four times more reflux episodes in a chalasia 
chair (a previously widely applied treatment) han when 
lying prone. The 30 ~ prone reversed Trendelenburg posi- 
tion is nowadays generally recommended and accepted 
as an essential element of treatment [32]. As a result of 
these paediatric studies, identical treatment recommen- 
Table 2. Schematic herapeutic approach 
Phase 1 
1 A. Position: prone reversed (head elevated) Trendelenburg 
position (30 ~ ) 
1 B. Milk-thickening a ents: Bean gum, St. John's bread 
(Nutriton, Carobel, Nestargel, Gumilk, Gelopectose) 
1 C. Dietary recommendations 
Increased frequency, small volume 
1 D. Alginic acid (+ antacid) (Gaviscon, Algicon) 
Phase 2 
Prokinetics: Cisapride (Prepulsid, Propulsin, Alimix) a 
[If symptoms are resistant tocisapride: domperidone 
(Motilium), metoclopramide (Primperan), alizapride 
(Litican), betanechol] 
Phase 3 
3 A. Hz-blockers: cimetidine (Tagamet), ranitidine (Zantac, 
Azantac, Raniplex, Zantic, Sostril) a, famotidine 
(Pepcidine, Pepdin, Pepdul, Ganor), etc. 
3 B. "Experimental" treatment: sucralphate (Ulcogant, Keal, 
Ulcar), omeprazole (Losec, Logastric, Mopral, Antra), 
misoprostil (Cytotec), etc. 
Phase 4 
Surgery (Nissen fundoplication, Thal fundoplication, 
anterior gastropexya of Boerema, etc.) 
a NOW that the European markets are "open", communication 
would be simplified ff drugs would have identical names in all 
countries 
dations have been advised in adults [25]. The prone re- 
versed Trendelenburg position is sufficient to treat GOR 
in about 25% of infants with uncomplicated GOR (re- 
gurgitations). According to the personal experience of 
one of the members of this Working Group, positional 
treatment is efficient even in 75% of regurgitating babies. 
However, positional treatment is in practice very diffi- 
cult to apply correctly in infants and rather uncomfort- 
able for babies, since they have to be tied up in their 
beds or cot to prevent them from sliding down under the 
blankets, since an angle of 30 ~ has to be achieved and 
maintained. 
Phase 1. B. milk-thickening agents. It is believed that the 
increased viscosity of thickened feeds will reduce the 
episodes of reflux, but it has been shown (by pH moni- 
toring and scintigraphy) that their effect is unpredictable 
[2, 34]. These products are mostly bean gum prepara- 
tions from St. John's bread, a galactomannan (Nutriton 
1 g/100 ml, Carobel, NestargeL Gumilk), although sodi- 
um carboxymethylcellulose can also be used for this pur- 
pose (Gelilact, 1 g/100 ml). Nestargel is carob seed flour 
containing 3.5% calcium lactate. Gelopectose is a French 
product, and is a combination of pectin and cellulose. 
Bean gum preparations are fermented in the colon, pro- 
viding a small energetic gain for the organism, and they 
can cause abdominal pain and diarrhoea. The use of cel- 
lulose might decrease postprandial g ycaemia. Products 
such as cereals or rice extracts are not appropriate for 
thickening of the feeds, since their properties are rapidly 
modified (hydrolysation) i  the stomach. 
To thicken the foods seems asafe approach with good 
clinical results, since in most Of the infants the observed 
symptoms of regurgitations and emesis decrease. How- 
ever, results of investigations show that in a number of 
patients the number of reflux episodes do indeed de- 
crease, but that the duration of the remaining episodes i
prolonged, resulting in an almost identical reflux index 
(percentage of time with pH below 4.0) [42]. Data sug- 
gest that an impaired oesophageal motility is not only 
the cause of the GOR disease, but that it may also delay 
the clearance of the thickened refluxed material. As a 
result, thickened feeds may not be appropriate in pa- 
tients with oesophagitis. 
Phase 1. C. dietary advice. It is difficult o formulate gen- 
eral dietary guidelines, since a number of these recom- 
mendations have contradictory consequences. Increased 
frequency of feeding, for one, will increase the number 
of postprandial neutral refluxes, but will decrease the 
number of acid reflux episodes. As a consequence, di- 
etary advice have to be tailored according to the needs of 
each individual patient. 
Increased frequency but decreased volume of feeding 
The ancient approach of decreased volume of feeding 
but at a higher frequency certainly has advantages (when 
the volume ingested is smaller, there is less volume to 
regurgitate), but also has disadvantages. Reflux occurs 
mostly during the postprandial periods: by feeding more 
frequently, the number of postprandial periods increases. 
707 
Low-fat high-carbohydrate formula 
Gastric emptying is enhanced with this kind of feeding 
(e.g. follow up formula). As a consequence, the dura- 
tion of buffering of the gastric acidity is shortened, and 
oesophageal pH monitoring detects more postprandial 
acid reflux episodes with this kind of feeding if compared 
to a regular formula. The choice of feeding has to be de- 
termined individually: enhancing astric emptying will 
decrease the number of reflux episodes (independent of
the pH), but will increase the number of acid episodes. 
Whatever feeding is prescribed, it should in any case suf- 
fice for the nutritional needs of the infant. 
Dietary advice in (older) children 
An anti-reflux regimen consists of a diet with normal to 
low fat, avoiding chocolate, coffee, tea, cola and other 
cabornated drinks, spicy foods, chilled beverages and/or 
food. Smoking also should be discouraged. Late evening 
meals and snacks should be restricted. Weight loss is a 
traditional component of reflux treatment in adults, but 
it is not recommended in children unless there is evi- 
dence of obesity. Drugs that may decrease the lower 
oesophageal sphincter pressure (xanthines and their de- 
rivates) should be avoided when possible. 
Phase 1. D. antacids. Antacids are reported to be effec- 
tive in the treatment of GOR [7, 29]. Gaviscon (a combi- 
nation of an antacid and sodium salt of alginic acid, 1- 
2g/100 ml) is as effective as antacids and appears to be 
relatively safe, since only a limited number of side-ef- 
fects have been reported. Dimethiconum (Polysylon Gel, 
Lefax, Sab Simplex, Elugan) is very popular in some re- 
gions, and used as - although it is not - an antacid, and 
in other regions it is rather used against bloating, flatu- 
lence and infant colic (although no reliable study is avail- 
able to prove that it is better than placebo for this indica- 
tion). One should not forget he activity of antacids (buf- 
fering gastric acidity) when analysing results of pH moni- 
toring in such patients. Occasional formation of large be- 
zoar-like masses of agglutinated intragastric material has 
been reported with the use of Gaviscon, and it can in- 
crease the sodium content of the feeds to an undesirable 
degree especially in preterm infants (1 g Gaviscon pow- 
der contains 46 mg sodium, and the suspension contains 
twice this amount of sodium) [29]. Dimethiconum con- 
tains very little sodium (0.036 mEq or 9.84mg Na § per 
15 g gel). Algicon has a low sodium load (but a high 
aluminium content as anion instead of sodium) with the 
same alginate amount, and a much better taste as Gavis- 
con. 
Experience with other antacids (Gelusil, Maalox, 
Muthesa, Mylanta, etc.) is limited in infants. 
Phase 2 therapy 
Prokinetics. Cisapride (Prepulsid, Propulsin, Alimix, 
0.4-1.2mg/kg/day in 3-4 doses, mean 0.8mg/kg/day) 
gives encouraging results [22, 26]. It is a non-dopamine- 
receptor blocking, prokinetic drug [36]. Cisapride en- 
hances gastro-intestinal contractile amplitude and im- 
proves antroduodenal co-ordination. It increases the 
lower oesophageal sphincter pressure and oesophageal 
contractility in normal volunteers [10] and in patients 
with decreased lower oesophageal sphincter pressure 
[9]. There is now considerable weight of evidence sug- 
gesting it is the drug Of first choice in GOR. Almost all 
studies have shown good short- and long-term control 
of GOR, with improved oesophageal motility and the al- 
most complete absence of serious ide-effects. It is possi- 
ble that cisapride is less effective in postprandia ! reflux, 
as reported by Holloway [20]. It should be stressed that 
cisapride is not an anti-emetic drug and has little effect 
on acute vomiting. Nevertheless, cisapride appears to be 
more effective than other drugs improving motility. Up 
to now, no serious side-effects have been reported. In 
our opinion, this drug can certainly be administered to 
treat uncomplicated GOR disease in infants before per- 
forming complementary investigations. Reported side- 
effects are all minor and transient: colic, diarrhoea, 
headache, drowsiness. In non-responders to cisapride, 
other drugs (domperidone (Motilium, l mg/kg/day), 
metoclopramide (Primperan, 0.5 mg/kg/day), alizapride 
(Litican, 2-4mg/kg/day), bethanechol (widely used in 
the United States of America but not marketed in Eu- 
rope) can be considered. Side-effects are more frequent 
and more serious with these drugs than with cisapride 
[19, 42, 44]. Aggravation of symptoms with metoclopra- 
mide has been reported [27]. Domperidone is reported 
to be as effective as metoclopramide, and has the impor- 
tant advantage of causing less dystonic reactions (tre- 
mors) in babies and also less anxiety and gynaecomastia 
[14, 17, 28, 35]. Transient gastro-intestinal pain, diar- 
rhoea, skin rash, drowsiness, extrapyramidal reactions 
and increased serum prolactin levels have been reported 
with all these drugs (except with cisapride) [14]. 
Phase 3 treatment 
Phase 3A therapy: H2-receptor blockers. It is not useful 
to combine antacids uch as alginic acid with acid secre- 
tion inhibitory drugs such as Hz-receptor blockers. Hz- 
receptor blocking agents like cimetidine (Tagamet, 24- 
30mg/kg/day) and ranitidine (Zantac, 4-6mg/kg/day 
IV or 10-15 mg/kg/day PO (in France this product is 
marketed as Azantac and Raniplex, in Germany as Zan- 
tic and Sostril)) have been used in GOR particularly 
when oesophageal symptoms predominate but results are 
equivocal [11, 21, 26]. Hz-antagonists have the incon- 
venience of causing a rebound nocturnal acid secretion 
[15, 40, 41]. The doses for infants of new Hz-receptor 
blockers are not known (famotidine (Pepcidine Pepdin 
in France, Pepdul and Ganor in Germany)), nizatidine 
(Calmaxid, Panaxid). The efficacy of these drugs on 
GOR cannot be evaluated by pH monitoring because 
they inhibit gastric acid secretion. However, endoscopy 
can indicate improvement of oesophagitis. 
Phase 3B therapy. Medical management of GOR in adults 
has greatly changed since it was reviewed by Bennett in 
1976 [4]. Many new drugs (Na+/K+-ATP-ase blockers, 
mucus protecting agents, etc.) have been developed (miso- 
prostil (Cytotec 200), sucralphate (Ulcogant-Keal or UI- 
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car in France), omeprazole (Losec, Logastric, Mopral in 
France, Antra in Germany, [30], etc.). Experience with 
these drugs is very limited in infants and children, although 
omeprazole is being more and more used with excellent 
results. Omeprazole has been shown to be effective in sup- 
pressing the acidity in patients with gastric stress ulcer(s) 
and also in neurologically impaired children. Sucralphate 
was shown to be as effective as cimetidine for oesophagitis 
in children [1]. The newest drugs, serotonin antagonists, 
are currently being evaluated in oncological patients re- 
ceiving emetic hemotherapy (ondansetron (Zofran), etc.) 
which specifically influence the vomiting centre in the 
brain. The indication of serotonin antagonists i limited 
to vomiting induced by chemotherapy. 
Phase 4 therapy 
Surgical considerations in adults for anti-reflux treatment 
were recently reviewed by Siewert and Feussner [39]. 
Nissen fundoplication is the preferred procedure in a 
number of centres, although the number of centres pre- 
ferring the Thal procedure appears to be comparable. 
More techniques do exist (e.g. anterior gastropexy of 
Boerema, etc.) and provide also good results. It is not 
the aim of this paper to discuss the differences between 
all surgical possibilities. The natural history of spontane- 
ous improvement in infants and young children means 
that surgery should usually be postponed until medical 
therapy has been exhausted [31]. In life-threatening GOR 
disease or in children with pre-existing neurological dis- 
ease surgery may be indicated earlier. There is, how- 
ever, no excuse for persisting with ineffective medical 
management of a process that may result in growth- 
stunting, chronic illness, persistent pain, oesophageal 
scarring, or even death [23]. 
Suggested iagnostic and therapeutic approach 
for different patient groups 
Before suggesting practical approaches regarding the in- 
vestigation and treatment of GOR, we would like to 
stress once more that vomiting or GOR is a non specific 
manifestation, and that either might be a symptom of an 
underlying disease. One should never forget to search 
for other causes of vomiting in unclear situations. 
Four groups of patients will be discussed. First, in- 
terest is focussed on GOR disease in patients with un- 
complicated GOR (mostly restricted to regurgitating in- 
fants, under 1 year of age). In a second paragraph, a
proposal is made for optimum management in patients 
with complicated GOR disease (symptoms uggestive 
for oesophagitis). An approach is proposed for the man- 
agement of patients with atypical presentations of GOR. 
The main difference between patients with uncompli- 
cated and complicated GOR on the one side and those 
with atypical presentations on the other side, is that the 
latter do not vomit or regurgitate. In a last, short para- 
graph, we deal with a subgroup of these patients, severe- 
ly neurologically impaired children. 
Patients with uncomplicated GOR 
This group of patients presents with repetitive regurgita- 
tions (and only seldom real vomiting). However, dif- 
ferentiation between regurgitations and vomiting or be- 
tween regurgitations and rumination is sometimes dif- 
ficult on clinical grounds. Most of the time, this form of 
presentation is restricted to infants (< 1 year). They 
have none of the complications related to GOR, such as 
failure to thrive or haematemesis. It is not always evi- 
dent in this patient group whether the parental complaints 
relate to physiological regurgitations orwhether egurgi- 
tation is too frequently and suggests GOR disease. 
Contrary to recommendations that all infants with 
uncomplicated GOR be investigated [37], the Working 
Group advices that treatment may be started in these in- 
fants without performing complementary investigations 
(and this for scientific, ethic and economic reasons), 
since reflux disease can be diagnosed confidently in the 
majority of this group of patients on the basis of history 
and a trial of medical management (phase i and 2). Treat- 
ment recommendations start with "phase-l". "Phase-2" 
treatment can be started before investigations are per- 
formed. "Phase-3" treatment is only indicated in compli- 
cated GOR disease, after appropriate investigations of 
the patient. 
However, if the results of the therapeutic trial are un- 
satisfactory, and parents persist in reporting complaints 
of symptoms (despite the necessary efforts trying to con- 
vince and reassure the parents about he physiologial na- 
ture of the complaints), pH monitoring may be perform- 
ed to document the reflux (Fig. 1). If the result of this in- 
vestigation is within normal ranges, GOR disease is un- 
likely, albeit in some cases, the diagnosis of GOR dis- 
ease should be reconsidered (and attention given to "sec- 
ondary" GOR) and/or other investigations should be 
performed to document GOR disease (e.g. echography 
Uncomplicated GOR [ 
No investigations 
Phase 1 (1-2 weeks) 
Phase 2 (1-3 weeks) 
?GOR? a 
pH monitoring 
I 
4, 
normal 
?? GOR ?? 
4, 
abnormal 
? endoscopy (malformation?) 
(oesophagitis?) b
? upper gastro-intestinal 
barium stud ies  
? therapy 
a Reconsider the diagnosis of GOR 
b If oesophagitis is present ,  see  Fig. 2 (complicated GOR) 
Fig. 1. Schematic diagnostic/therapeutic approach inpatients with 
uncomplicated GOR 
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or scintigraphy if non-acid reflux pathology issuspected). 
At this stage, the long list of "primary" disorders that 
may present with GOR should be (re)considered. When 
pH monitoring data are abnormal, complications of 
GOR-pathology could be present, and other investiga- 
tions should be performed in a number of cases, includ- 
ing endoscopy for peptic oesophagitis orupper gastro-in- 
testinal barium studies for anatomical malformations 
and swallowing disorders (Fig. 1). Manometry may be 
helpful to detect a (partial) achalasia of the lower oesoph- 
ageal sphincter or other oesophageal motiliy disorders 
which might help in the understanding of failure of pro- 
kinetis. At this stage, the patient should be referred to a 
specialised centre. 
Patients uspected ofoesophagitis 
These patients present with frequent vomiting and symp- 
toms suggestive of complications (haematemesis, retro- 
sternal and epigastric pain, etc.) (cf. Table 1). 
Upper gastro-intestinal endoscopy is the investigation 
of first choice for the detection of peptic oesophagitis or 
underlying anatomical malformations (Fig. 2). This tech- 
nique should only be performed by experienced and qual- 
ified paediatric gastro-enterologists and should always 
be a duodeno-gastro-oesophagoscopy. If the question be- 
ing asked is restricted to underlying anatomical malfor- 
mations, upper gastro-intestinal series can also be con- 
sidered. Histological criteria for the diagnosis of oesoph- 
agitis are presented in Table 3. 
Treatment should in all cases consist of "phase-1 and 
-2" therapy. Since there are reports that "minimal" 
oesophagitis (redness) can heal with "phase-2" alone, as 
a rule, it will not be necessary to administer "phase-3A" 
treatment (Hz-blocker). Moreover, H2-blockers do not 
decrease the incidence and duration of the reflux epi- 
4, 
No 
Phase 2 treatment 
1-3 months 
I Complicated GOR I 
4, 
Endoscopy a 
? Oeso > Grade 3 b 
Yes  
Phase 3 treatment 
4-12 weeks  
Repeat endoscopy 
4, 
Yes 
Invest igat ions 
prior to surgery 
? Oeso > Grade 3 a 
4, 
No 
Stop Phase 3 treatment 
Continue Phase 2 
a Endoscopy is the preferred technique for oesophagitis; endos- 
copy and/or X-ray of oesophagus and stomach are appropriate 
to detect anatomical malformations 
bAccording to criteria clarified in Table 3 
Fig. 2. Schematic diagnostic/therapeutic approach inpatients with 
complicated GOR 
Table 3. Criteria for the diagnosis of GOR and oesophagitis onen- 
doscopic biopsies (according toK. Geboes) [16] 
Histologic riteria Clinical 
diagnosis 
Grade 0 Normal Normal 
Grade 1 a) Basal zone hyperplasia Reflux 
b) Elongated stromal papillae 
c) Vascular ingrowth 
Grade 2 Polymorphonuclear c llsin the Oesophagitis 
epithelium, the lamina propria 
or both 
Grade 3 Polymorphs with epithelial Oesophagitis 
Grade 4 Ulceration Oesophagitis 
Grade 5 Aberrant columnar epithelium Oesophagitis 
Unusual presentation I 
4, 
pH monitoring 
Normal Abnormal 
4, 4, 
?? GOR ?? Phase 2 treatment 
I 
Repeat pH monitoring 
1-6 months 
I * + 
Normal Abnormal 
iI I' 
Stop treatment 
6-12 months 
4, 
Follow-up 
Clinical follow-up 
Satisfactory No change 
'1 I 
False diagnosis Complete 
investigations 
Fig. 3. Schematic diagnostic/therapeutic approach inpatients with 
unusual presentations of GOR 
sodes, they simply neutralise partially the acidity of the 
reflmxed material. Immediate or early surgery is rarely 
indicated in life-threatening conditions where medical 
management will be of no benefit (e.g. in major grade 
IV oesophagitis, the efficacy of drugs like omeprazole 
should first be tried out (phase 3.B.)). 
After about 4 to 12 weeks of treatment, a control endos- 
copy should be performed. If normalised, H2-blockers 
can be stopped. Other drugs (phase 1 and 2) can be con- 
tinued for a prolonged period, depending on the clincial 
situation. In patients who have suffered asevere oesoph- 
agitis, we recommend a third endoscopy about 3 months 
after the discontinuation of the H2-blockers to recognize 
exacerbation. 
If symptoms and/or the oesophagitis do not improve 
despite adequate treatment, upper gastro-intestinal series 
are recommended to exclude anatomical problems uch 
as gastric volvulus, intestinal malrotation, annular pan- 
creas, etc. 
"Phase-4" therapy, surgery, although not devoid of 
risks and side-effects, may be inevitable in some pa- 
tients, who fail to improve with "phase-3B" treatment. 
Surgery can be life-saving in severely affected patients 
(notably the neurologically impaired children with recur- 
rent and life-threatening aspiration, etc.). Prior to sur- 
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gery, a full diagnostic work-up may include upper gas- 
tro-intestinal series, manometry, endoscopy, pH moni- 
toring and gastric emptying studies, all contributing to the 
decision to operate, and the choice of surgical procedure. 
Patients with unusual presentations ofGOR 
The most obvious difference between this patient group 
and the patients with uncomplicated and complicated re- 
flux, is that this patient group does not present with 
emesis and regurgitations (Table 1). Since these patients 
do not vomit, their GOR disease is "occult". Before con- 
sidering GOR as a cause of the symptoms, classic causes 
of the manifestations eed to be excluded, such as allergy 
in a wheezing patient, tuberculosis ina patient with chronic 
coughing. Unusual presentations are listed in Table 1. 
If GOR disease is suspected in these infants and chil- 
dren, a pH monitoring of long duration is the examina- 
tion of choice. The approach advocated by Richter and 
Castell in 1983 [38], in which oesophageal pH metry was 
suggested as the very final investigation for patients us- 
pected of having GOR can no longer be recommended, 
In this group of patients, pH monitoring may need to be 
combined with simultaneous other investigations in order 
to relate pH changes to events (e.g. polysomnography in 
the infants presenting with an Apparent Life Threatening 
Event). In patients uspected of pulmonary aspiration, 
a scintigraphy might prove the association (although a 
negative scintigraphy does not exclude reflux related as- 
piration, and the therapeutic approach will be identical. 
If pH monitoring is abnormal or if events are clearly 
related to pH changes, "phase-2" treatment is indicated. 
If the pH monitoring data are extremely abnormal, an 
endoscopy of the upper gastro-intestinal tract might be 
indicated to diagnose oesophagitis. Repeat pH monitor- 
ing under treatment conditions in this group with un- 
usual or atypical GOR disease, combined with regular 
clinical observation may prove further evidence sub- 
stantiating the diagnosis of GOR disease and evaluating 
the efficacy of treatment. Treatment can be stopped 
after 6-12 months, since a possible mechanism for GOR 
in association with unusual manifestations may be self- 
perpetuating ("GOR as a factor inducing GOR by itself" 
or "GOR perpetuates GOR"). Once reflux occurs, acid 
gastric contents containing pepsin and sometimes bite 
comes into contact with the oesophageal mucosa, which 
increases the oesophageal permeability o acid and makes 
the oesophageal mucosa much more suspetible to inflam- 
matory changes. Oesophageal inflammation, even re- 
stricted to the lower oesophagus, impairs lower oesopha- 
9 geal sphincter pressure and function, and favours GOR 
[12, 18]. Inflammation and dysfunction of branches of 
the adjacent vagus nerve also reduce the lower oesopha- 
geal sphincter pressure, favour pylorospasm and thereby 
inducing a vicious circle of events ustaining GOR [6]. 
Long-term clinical follow up of these patients i necessary. 
Severely neurologically impaired children 
Neurologically impaired children suffer very frequently 
from GOR pathology and its complications. These chil- 
dren are often under specialised follow-up, we will there- 
fore only give brief recommendations. The pathophysio- 
logical mechanism of GOR in these children is particu- 
larly multifarious: the neurological disease itself (delayed 
oesophageal clearance and delayed gastric emptying), the 
fact that most of these children are bedridden (gravity), 
many are constipated (increased abdominal pressure), 
etc. GOR disease should be investigated systematically, 
and prolonged oesophageal pH monitoring is the prefer- 
red technique. Endoscopy to evaluate the condition of 
the oesophageal mucosa is indicated in the children with 
severe GOR disease. Since it might be difficult to recog- 
nise GOR disease on clinical grounds in mentally retarded 
children, the disease can evolve during years and lead to 
severe complications such as oesophageal stricture or Bar- 
rett's oesophagus. Natural resolution of GOR is less com- 
mon in children with neurological disease. If phase-2 treat- 
ment (cisapride) does not provide satisfactory control of 
GOR-disease, therapy should be more invasive. However, 
it is our feeling that the efficacy of prokinetics in combina- 
tion with Hz-blockers or omeprazole should be evaluated 
prior to surgery. Proton-pump inhibitors (omeprazole) 
will probably appear useful in this situation, although 
objective paediatric data are (still) lacking. Although 
controlled studies in large populations are not available, 
it appears that a (endoscopic percutaneous) gastrostomy 
together with a Thai-procedure (amodified Nissen where 
the stomach is wrapped around 270 ~ of the lower oesoph- 
agus often performed laparoscopically), with continued 
cisapride may be the preferable therapy in severely neu- 
rologically impaired children. Whatever the choice of re- 
flux therapy, appropriate investigations and treatment of 
GOR in these children are mandatory. There is an ur- 
gent need for blind prospective multi-centric studies on 
the diagnosis and treatment of GOR disease in neuro- 
logically impaired children. The opinion of centres differ 
regarding "best" treatment in these patients: it is not 
e.g. clear if a life-long treatment with prokinetics and 
omeprazole would be preferable to surgery. 
Conclusion 
The diagnostic approach of GOR disease in infants and 
children principally depends on its presenting features. 
Infants with typical symptoms of GOR without compli- 
cations should be treated without prior investigation. 
Endoscopy, in specialised centres, is recommended if 
oesophagitis i suspected. Long-term oesophageal pH 
monitoring is nowadays the investigation of choice and 
occupies a central position in the diagnostic approach to 
the patient suspected of unusual or atypical manifesta- 
tions of GOR disease (occult GOR disease). Only if 
non-drug treatment (phase 1) is unsuccessful, cisapride 
is recommended. Cisapride has two advantages: it is 
probably the most adapted rug available, and no serious 
ide-effects have been reported. 
The authors hope that these recommendations of ap- 
proach in the diagnosis and treatment of uncomplicated, 
severe and occult GOR disease in infants and children 
will help the family paediatrician i  caring for his pa- 
711 
tients with respect  o these frequent ly encountered con- 
ditions. 
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